scispace - formally typeset
D

Daniel C. Chung

Researcher at Harvard University

Publications -  307
Citations -  27050

Daniel C. Chung is an academic researcher from Harvard University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 69, co-authored 290 publications receiving 24211 citations. Previous affiliations of Daniel C. Chung include University of Pennsylvania & Google.

Papers
More filters
Journal ArticleDOI

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

TL;DR: It is shown that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
Journal Article

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

TL;DR: In this article, a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients.
Journal ArticleDOI

Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

TL;DR: Data suggest that, through recruitment of tumor-infiltrating immune cells, fusobacteria generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression, and this work finds that F.nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis.
Journal ArticleDOI

Gastroenteropancreatic neuroendocrine tumours.

TL;DR: To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling, and more-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed.